Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain.
Harsha Shanthanna, Sam Eldabe, David Anthony Provenzano...
https://pubmed.ncbi.nlm.nih.gov/37001888Actively Recruiting
Led by Third Military Medical University · Updated on 2025-01-28
10
Participants Needed
4
Research Sites
17 weeks
Total Duration
T
Third Military Medical University
Lead Sponsor
B
Beijing Tiantan Hospital
Collaborating Sponsor
Adrenomyeloneuropathy (AMN) is a rare genetic disorder caused by mutations in the ABCD1 gene, leading to muscle weakness, reduced ankle joint movement, and nerve damage in the lower limbs. This condition causes a progression from increased muscle tone to paralysis, severely affecting walking and quality of life. Current treatments are limited, so researchers are exploring new options to improve symptoms and function in adults with AMN. This study evaluates spinal cord stimulation (SCS) as a potential treatment for lower limb muscle tone and movement problems in AMN patients. SCS involves implanting electrodes near the spinal cord and connecting them to a nerve stimulator that sends electrical pulses to stimulate nerves and improve motor function. After implantation, patients receive rehabilitation and use the stimulator regularly with specific schedules for continuous or intermittent stimulation. Participants will undergo preoperative evaluations followed by the implant surgery. They will then have scheduled assessments before and after starting stimulation at one week, four weeks, and follow-ups at four weeks and six months after hospital discharge. Researchers will measure walking ability, motor function, nerve signals, MRI scans, pain, and safety to understand the effects and risks of SCS in improving lower limb function in AMN patients over time.
CONDITIONS
Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants undergo initial assessments of motor function, neurological status, and other relevant examinations before surgery.
1 visit (in-person)
Duration - 1 to 2 weeks
Participants receive implantation of a lumbar spinal cord nerve stimulator and pulse generator followed by recovery and transfer to rehabilitation centers.
1 surgical visit and up to 2 post-operative visits
Duration - At least 4 weeks
Participants undergo electrical stimulation therapy using the implanted device, with stimulation applied at least three days per week for 4 to 8 hours per day.
3 visits during treatment (before device activation, 1 week after activation, and 4 weeks after activation)
Duration - 6 months
Participants return for longer-term assessments of motor function and safety up to six months after hospital discharge.
2 visits after discharge (4 weeks and 6 months post-discharge)
Total: 4 locations
1
Beijing TianTan Hospital
Beijing, Beijing Municipality, China, 100070
Active, Not Recruiting
2
The 958 Hospital of Chinese People's Liberation Army, The Jiangbei Campus of Southwest Hospital, The First Affiliated Hospital of Army Medical University
Chongqing, Chongqing Municipality, China, 400020
Actively Recruiting
3
the Southwest hospital
Chongqing, Chongqing Municipality, China, 400038
Actively Recruiting
4
Jingmen No.1 People's Hospital
Jingmen, Hubei, China, 448000
Active, Not Recruiting
L
Liang Tan, Ph,D
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Harsha Shanthanna, Sam Eldabe, David Anthony Provenzano...
https://pubmed.ncbi.nlm.nih.gov/37001888Richard North, Jane Shipley, Joshua Prager...
https://pubmed.ncbi.nlm.nih.gov/17995571Marc P Powell, Nikhil Verma, Erynn Sorensen...
https://pubmed.ncbi.nlm.nih.gov/36807682Sachin Kandhari, Dewaker Sharma, Sachin Samuel...
https://pubmed.ncbi.nlm.nih.gov/35271446Fabien B Wagner, Jean-Baptiste Mignardot, Camille G Le Goff-Mignardot...
https://pubmed.ncbi.nlm.nih.gov/30382197Andreas Rowald, Salif Komi, Robin Demesmaeker...
https://pubmed.ncbi.nlm.nih.gov/35132264Shiyu Luo, Haonan Xu, Yi Zuo...
https://pubmed.ncbi.nlm.nih.gov/31916220Eduardo Martin Moraud, Marco Capogrosso, Emanuele Formento...
https://pubmed.ncbi.nlm.nih.gov/26853304Andrew K Rock, Huy Truong, Yunseo Linda Park...
https://pubmed.ncbi.nlm.nih.gov/30898269D M Dooley, J Sharkey, W Keller...
https://pubmed.ncbi.nlm.nih.gov/310508